Drotrecogin Infectious disease An agent used to manage severe sepsis
References in periodicals archive ?
Previously, Dr Fisher led Eli Lilly & Co's Xigris global product team, divisional vice president for global pharmaceutical research and development at Abbott Laboratories, chief medical officer and executive vice president of Cardiome Pharma Corp as well as a member of the Defense Science Research Council.
More concretely, it provides several examples of irreproducibility in patents on blockbuster drugs--Prempro, Xigris, Plavix, and Avastin--and discusses some of the social costs of the misalignment between good clinical practice and patent doctrine.
Esta proteina fue fabricada por la empresa Eli Lilly como XIGRIS [Drotrecogina alfa (activada)], para tratar alteraciones de la coagulacion inducidas por sepsis con alto riesgo de muerte en humanos, desde noviembre del ano 2001 hasta octubre del 2011.
Following a number of high-profile cases, such as the 2010 recall of Cylert, a central nervous system stimulant to treat ADHD/ADD, and the 2011 recall of Xigris, a treatment for severe sepsis and septic shock that was found to give patients no survival benefit, there is increased pressure to guarantee that pharmaceutical formulations are safe to use.
LG Chemicals Zaveinex Zdyus Biogen Shanpoietin Shantha Interferon Biotechnics beta 1a Vintor-Nephrology/Epofer- Emcure Avonex Nicholas Haematinics Piramal Wepox Wockhardt Blood Factor VIII - Hemophilia Federation of India Zyrop Zdyus Biogen Follicle Stimulating Hormone (FSH) Hepatitis B Vaccine Gonal-F Serum Institute of India Bevac LG Follimon Inj LG Follimon LG Inj Chemicals Biovac B Wockhardt Tissue German Plasminogen Remedies Acticator Engerix-B GlaxoSmithKline Alpha Drotrecogin Enivac HB Panacea Biotec Xigris Eli Lilly and Company Gene Vac-B Serum Institute of India LGEuvax B Inj LG Chemicals Revac B Bharat Biotech Shanvac B Shantha Biotechnics Source: http://www.
FDA drug safety communication: Voluntary market withdrawal of Xigris [drotrecogin alpha (activated)] due to failure to show a survival benefit.
Xigris (drotrecogin alfa [activated]) to be withdrawn due to lack of efficacy: PROWESS-SHOCK study shows no gain in 28-day survival of septic shock patients [Press release].
Xigris [drotrecogin alfa (activated)]: market withdrawal - failure to show survival benefit.
On 25 October 2011, both the US Food and Drug Administration (FDA) (4) and European Medicines Agency (EMA) (5) announced their intentions to withdraw marketing rights for Xigris in the USA and Europe.
The committee asked the manufacturer to conduct a new test to confirm that "the benefits of Xigris outweigh its risks to patients with septic shock.
M2 PHARMA-October 25, 2011-Lilly withdraws Xigris, updates 2011 financial outlook(C)2011 M2 COMMUNICATIONS